Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
AJ Scheen - Nature reviews endocrinology, 2020 - nature.com
The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …
Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors
CS Wilcox - Hypertension, 2020 - Am Heart Assoc
Empaglifolzin, canagliflozin, and dapagliflozin are SGLT2 (sodium-glucose linked
transporter type 2) inhibitors for treatment of type 2 diabetes mellitus that also reduce blood …
transporter type 2) inhibitors for treatment of type 2 diabetes mellitus that also reduce blood …
Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and …
C Li, S Liang, L Gao, H Liu - PloS one, 2021 - journals.plos.org
Background and aims Glucose lowering agents that reduce the risk of major adverse
cardiovascular events (MACE) would be considered a major advance. The reduction of …
cardiovascular events (MACE) would be considered a major advance. The reduction of …
The role of SGLT2 inhibitors in atherosclerosis: a narrative mini-review
A Pahud de Mortanges, D Salvador Jr… - Frontiers in …, 2021 - frontiersin.org
Objective: Sodium glucose cotransporter 2 inhibitors (SGLT2-is) are antidiabetic drugs that
improve glycemic control by limiting urinary glucose reuptake in the proximal tubule. SGLT2 …
improve glycemic control by limiting urinary glucose reuptake in the proximal tubule. SGLT2 …
Low-dose empagliflozin improves systolic heart function after myocardial infarction in rats: regulation of MMP9, NHE1, and SERCA2a
J Goerg, M Sommerfeld, B Greiner, D Lauer… - International Journal of …, 2021 - mdpi.com
The effects of the selective sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin
in low dose on cardiac function were investigated in normoglycemic rats. Cardiac …
in low dose on cardiac function were investigated in normoglycemic rats. Cardiac …
The role and mechanisms of microvascular damage in the ischemic myocardium
BH Zhao, A Ruze, L Zhao, QL Li, J Tang… - Cellular and Molecular …, 2023 - Springer
Following myocardial ischemic injury, the most effective clinical intervention is timely
restoration of blood perfusion to ischemic but viable myocardium to reduce irreversible …
restoration of blood perfusion to ischemic but viable myocardium to reduce irreversible …
The vascular disease of diabetic kidney disease
Background: The incidence of cardiovascular disease (CVD) is increased in patients with
diabetic kidney disease (DKD). Summary: Aortic stiffness is a well-accepted biomarker for …
diabetic kidney disease (DKD). Summary: Aortic stiffness is a well-accepted biomarker for …
Sodium glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization in patients with type 2 diabetes mellitus: a systematic review and meta …
Aim To evaluate the impact of sodium glucose cotransporter 2 inhibitors (SGLT-2i) on risk of
heart failure hospitalization in patients with type 2 diabetes. Methods We searched the …
heart failure hospitalization in patients with type 2 diabetes. Methods We searched the …
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: a secondary analysis
KY Feng, JW Li, J Ianus, D de Zeeuw… - Diabetes, Obesity …, 2021 - Wiley Online Library
Aim To determine the reasons for hospitalizations in the CANagliflozin cardioVascular
Assessment Study (CANVAS) programme and the effects of the sodium‐glucose co …
Assessment Study (CANVAS) programme and the effects of the sodium‐glucose co …
[HTML][HTML] Does race/ethnicity influence the impact of new glucose-lowering agents on cardiovascular outcomes?—a comparison between Asian versus White patients
AJ Scheen - Annals of Translational Medicine, 2022 - ncbi.nlm.nih.gov
Cardiovascular disease (CVD) represents a major burden in patients with type 2 diabetes
(T2DM), with at least a twofold increase in myocardial infarction and ischemic stroke, and a …
(T2DM), with at least a twofold increase in myocardial infarction and ischemic stroke, and a …